France
AblaCare is pioneering a breakthrough in the Health Care sector by tackling infertility in women affected by Polycystic Ovary Syndrome (PCOS). Founded in 2017 and headquartered in France, this Paris-based company stands out with its unique approach: offering a less medicalized and more natural solution to ovulation restoration.
The company's flagship procedure is a simplified, less-invasive treatment designed to be both durable and typically needed only once, providing hope for women seeking to conceive naturally despite PCOS.
With a strong foundation and a promising therapeutic solution, AblaCare received a notable €10.00M Series A investment on 09 July 2019, primarily led by Sofinnova Partners, underscoring investor confidence in its innovative approach and potential market impact.
As they continue to advance, AblaCare represents a compelling opportunity for investors interested in transformative healthcare solutions, especially within the burgeoning fertility sector.
